You are here


Clinical Development Partnerships (CDP) is a joint initiative launched by Cancer Research Technology and Cancer Research UK. The CDP scheme aims to increase the number of successful new treatments for cancer patients by taking more novel oncology agents into clinical development. CDP combines CRT’s commercial know-how with the operational capabilities and translational and clinical expertise of the CRUK Centre for Drug Development. It brings promising anti-cancer agents, which companies are otherwise unable to develop, into clinical trials.

The initiative is primarily targeted at leading pharmaceutical and biotechnology companies who may require expertise, resource or capabilities to take forward novel agents in oncology. CDP offers these companies an alternative path for clinical development. It provides a unique opportunity to work with Cancer Research UK, the world's largest charitable funder of cancer research, and enables companies to realise the full potential of their oncology pipelines for the benefit of people with cancer.

Since its formation, CDP has seen 17 treatments enter the programme, with 12 currently in active development.

For more information about the CDP initiative, contact the team at:


 Click on the image to view our Clinical Development Partnerships (CDP) pipeline.



NCRI Cancer Conference 2016
November 6-9 2016, Liverpool

BIO- Europe Autumn 2016
November 7-9, 2016, Cologne


4 November 2016

Cancer Research UK and Cancer Research Technology partner with TYG Oncology to develop next generation cancer vaccine

Read the full press release here

7 December 2015

Nemucore Medical Innovations options clinical-stage Aurora Kinase Inhibitor GSK1070916 from CRT.

Read the full press release here

9 July 2015

Cancer Research UK and Cancer Research Technology announce partnership with Monopar Therapeutics to develop new oncology compound.

Read the full press release here